Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Rapid Response Innovation Awards, 2012
    Stimulation of Protein Clearance Mechanisms to Improve Clearance of Toxic Accumulations of Alpha-synuclein

    Objective/Rationale:             
    Alpha-synuclein protein accumulation in the brain causes neurotoxicity in Parkinson’s disease (PD). Neural cells have a protein degradation mechanism called the...

  • Novel Approaches to Drug Discovery for PD, 2012
    Cerium Oxide Nanoparticles in the Treatment of Parkinson’s Disease – Toxicity and Biodistribution Studies

    Promising Outcomes of Original Grant:
    In our prior years of funding from The Michael J. Fox Foundation, we tested the hypothesis that cerium oxide nanoparticles (CeONP) were a disease-modifying therapy...

  • Research Grant, 2012
    Collaborative Validation of Oxidized DJ-1 Antibodies For PD Biomarker Study

    Objective/Rationale:             
    We have developed antibodies against an oxidized form of DJ-1 using complementary approaches to be able to use them as a biomarker in PD.  A common problem in...

  • Rapid Response Innovation Awards, 2012
    CD163+ Macrophages as Tools for Neuroinflammatory Modulation in Parkinson’s Disease

    Objective/Rationale:
    Evidence in humans and in research models support a role for the immune system in the progression of Parkinson's disease. Our preliminary data suggest infiltration of peripheral...

  • Neurotrophic Factors Challenge, 2012
    Effects of Recombinant CDNF Protein in Alpha-synuclein Model of Parkinson’s Disease in Pre-Clinical Models

    Objective/Rationale:Neurotrophic factors have been explored as a novel treatment for Parkinson’s disease. Toxic effect of α-synucleinopathies, one of the hallmarks in PD pathophysiology, occurs in...

  • Target Validation, 2012
    Small Molecule Ligand for TrkB/TrkC as a Novel Therapeutic for Parkinson's Disease

    Objective/Rationale:        
    Ample evidence suggests that the neurotrophin (NT) receptors, TrkB and TrkC, would be particularly effective therapeutic targets for Parkinson’s disease (PD). Both...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.